~99.9% of people hospitalized with COVID-19 in May weren't fully vaccinated, AP reports
Andrew Dunn
6,804 posts
Andrew Dunn
@AndrewE_Dunn
Senior biopharma correspondent at @endpts | Previously @BusinessInsider @BioPharmaDive | [email protected] | Signal (sources only): adunn.68
- BREAKING: Alphabet's closely watched AI bio Isomorphic Labs has inked its 1st pharma deals, CEO @demishassabis told me. Eli Lilly and Novartis will pay $82.5 million upfront along with $2.9B in pot'l milestones to discover drugs. Scoop 🔗:
- NEW: CRISPR pioneer Feng Zhang is building a secretive new startup to solve gene-editing's biggest problem — getting into more parts of the body Meet Aera Therapeutics, which has raised $200 million to advance Zhang's work:
- Latest CDC data shows 1.4 million more COVID-19 shots administered Friday — 20 million given in total. Encouraging acceleration after a slow start: 23 days to give the first 5 million. 7 days for the next 5 million 6 days for the next 5 million 4 days for the next 5 million
- I don't even know if 2 jobs describes what @KizzyPhD has been doing, detailed in this @NidhiSubs interview Designing the SARS-CoV-2 vaccine by day and volunteering to talk with vaccine-hesitant people of color by night
- A Friday 🧵 for those who find this as interesting as me Here's how some basic biology research on memory by a tattooed neurobiologist in Utah is now playing a key role in Feng Zhang's gene-editing startup Aera (1/9)
- A new CDC case study: A bar in rural Illinois reopened in February. That's been linked to 46 COVID-19 cases, including one hospitalization. "These findings underscore the vast impact of a single event," CDC Director Rochelle Walensky said.
- NEW: A trio of young MIT scientists say their new AI model has made progress in predicting binding affinity, a key property in drug discovery Good affinity prediction has evaded other AI models, but Boltz-2 showed solid improvement:
- Finalized #JPM23 schedule just dropped — includes privately held companies Some startups to watch that are presenting: Ultima Genomics, ElevateBio, Tessera, Metagenomi, Mammoth, Arbor, Element, Umoja ...
- BREAKING: Moderna's coronavirus vaccine candidate succeeds in the final stage of trials. The Mass. biotech says the shot is 94.5% effective and easy to transport.
- The fabled PERSONAL NEWS tweet: Today’s my first day as Business Insider’s pharma and biotech reporter! So excited to keep covering the industry as part of BI’s healthcare team — get in touch, everyone.
- Farhad Siddique was a 19-year-old junior at UMD, victim in apparent double-murder-suicide. Rest in peace.
- This is pretty wild @RobertLKruse pointed out this trick in Moderna's slide, comparing its flu shot to a competitor The y-axis for Fluzone's shot is lower. That makes it look worse (and $MRNA's shot better) if glancing quickly and comparing the two graphs.
- UPDATED: Regeneron and Eli Lilly are now in the clinic with coronavirus antibody therapeutics. The hope is these drugs can be effective for BOTH preventing and treating COVID-19. Could be ready to use this fall, before vaccines are ready
